Australia ED market size 2004 =1.6*1.045/0.28 =5.97 b. (source: KKL financial statement 2001-2004, recent news reports) 12.38 10.32 8.60 7.16 5.97 ED Market Site ( with a growth 20%) 2008 2007 2006 2005 2004 Year
Competitive Analysis Brainstorming EBIT Impacts Statistic Insights Competitive Analysis Possible Scenario Recommendations Competitive Distantage Competitive Advantage Existing Portfolio YES - Three Key Issues Should KKL enter the ED market ?
Possible Scenario Brainstorming EBIT Impacts Statistic Insights Competitive Analysis Possible Scenario Recommendations Scenario 1 Scenario 2 Scenario 3 R & D Alliance Acquisition Stay outside* Acquisition Red Eye VS. Lipovitan Scenario3 : Acquire an ED brand name , Red Eye or Lipovitan? (Possible to acquire these brands due to their difficulties) Scenario 1 : Develop KKL’s own ED product Advantages ---- Possible higher profit margin, Disadvantages ----Technology, time, starting a new brand, advertisement Scenario 2 : Ally with current players, Frucor Advantages ---- enhance the competitiveness of the two companies; taking the advantage of Frucor leading position in ED market, Disadvantages ----- sharing the profits, challenges in management * When there is a threat of banning ED in Australia
Possible Scenario Brainstorming EBIT Impacts Statistic Insights Competitive Analysis Possible Scenario Recommendations Red Eye VS. Lipovitan Option 1: Red Eye Advantages ---- Already available in Australian market, faster entry Disadvantages ---- health concerns Option 2: Lipovitan Advantages ---- Healthier, broader range of customers (age group with large pop.) Disadvantages ----Completely new in Australian market, less attractive to teenagers
Recommendations
1. Integrate enterprise resources of the two companies, especially KKL's market power and distribution system and Lipoviatn's know-how, to build a leader role in the ED industry
2. Adapt the current marketing strategy to focus more on particular target market while continuing to be a broader-based beverage supplier
3. Invest on Research & Development to introduce more health ED products as responses to the scientific debates and legal regulations.
4. Also invest on innovation of existing CSD-BW divisions for new products with high profit margin
Brainstorming EBIT Impacts Statistic Insights Competitive Analysis Possible Scenario Recommendations The team suggests that KKL acquire Lipovitan as the optional solution, and the following issues needed to be considered at the strategic level:
0 comments
Post a comment